SCHEMBL21807309

SCHEMBL21807309

COc1nc2c(c(Oc3ccccc3C(F)(F)F)n1)CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.43
TNKS2 Q9H2K2 1/20 0.43
PARP2 Q9UGN5 1/20 0.43
P2RX3 P56373 5/20 0.42
ABHD6 Q9BV23 1/20 0.41
TRPC5 Q9UL62 1/20 0.40
P2RX7 Q99572 2/20 0.39
MAPT P10636 3/20 0.38
KDM4E B2RXH2 1/20 0.38
GRM5 P41594 1/20 0.38
GRM1 Q13255 1/20 0.38
MKNK1 Q9BUB5 2/20 0.38
RAF1 P04049 1/20 0.38
BRAF P15056 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
MTOR P42345 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21807467 0.89 P2RX7 (0.42) ABHD6TRPC5P2RX7KDM4EPTGDR2
SCHEMBL21807251 0.88 TRPC5 (0.44) PARP1TNKS2PARP2P2RX3TRPC5
SCHEMBL24433296 0.81 TRPC5 (0.37) PARP1TNKS2PARP2P2RX3TRPC5
SCHEMBL21807275 0.79 PARP1 (0.37) PARP1TNKS2PARP2P2RX3TRPC5
SCHEMBL21807357 0.78 TRPC5 (0.51) PARP1TNKS2PARP2TRPC5P2RX7
SCHEMBL29329810 0.78 TRPC5 (0.47) PARP1TNKS2PARP2TRPC5MAPT
SCHEMBL29330191 0.78 MKNK1 (0.43) PARP1TNKS2PARP2P2RX3MAPT
SCHEMBL29329811 0.77 TRPC5 (0.51) PARP1TNKS2PARP2P2RX3TRPC5
SCHEMBL21807317 0.76 TRPC5 (0.46) PARP1TNKS2PARP2TRPC5MKNK1
SCHEMBL21807333 0.76 P2RX7 (0.47) TRPC5P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113939295-B Pyridazinones and methods of use thereof 金翅雀生物公司 2025-05-16 CN disclosed
EP-4414365-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2024-08-14 EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 EP disclosed
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-05-19 US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 US disclosed
EP-3941475-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2022-01-26 EP disclosed
EP-3852533-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2021-07-28 EP disclosed
US-11046690-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2021-06-29 US disclosed
US-11046690-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2021-06-29 US disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 WO disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 WO disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 US disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 US disclosed
US-10654850-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2020-05-19 US disclosed
US-10654850-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2020-05-19 US disclosed
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-04-02 US disclosed
WO-2020061162-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN PARP1 2824/4885TNKS2 2412/4885PARP2 2100/4885
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GLS, ATP6V1B1, PDXK PARP1 3410/4885TNKS2 2308/4885PARP2 1845/4885
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN PARP1 2824/4885TNKS2 2412/4885PARP2 2100/4885
US-11046690-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN PARP1 2824/4885TNKS2 2412/4885PARP2 2100/4885
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN PARP1 2824/4885TNKS2 2412/4885PARP2 2100/4885
US-10654850-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN PARP1 2824/4885TNKS2 2412/4885PARP2 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.